Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 7/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13741720 | 0.93 | CDC7 (0.44) | CDC7DBF4PIM1MGLL | |
| Trifluoroacetic Acid SCHEMBL4092771 | 0.81 | L3MBTL1 (0.41) | CDC7DBF4L3MBTL1 | |
| SCHEMBL13741481 | 0.71 | CYP19A1 (0.44) | — | |
| SCHEMBL4096709 | 0.70 | MAPK14 (0.43) | — | |
| Trifluoroacetic Acid SCHEMBL4092665 | 0.66 | JAK2 (0.37) | CDC7DBF4PIM1MGLL | |
| SCHEMBL3356249 | 0.65 | ALDH1A1 (0.44) | CDC7DBF4PIM1L3MBTL1MGLL | |
| SCHEMBL26462950 | 0.65 | NOTUM (0.61) | — | |
| SCHEMBL30494229 | 0.65 | NOTUM (0.61) | — | |
| Hydrochloric Acid SCHEMBL324193 | 0.64 | ALDH1A1 (0.43) | CDC7DBF4PIM1L3MBTL1MGLL | |
| SCHEMBL15452734 | 0.62 | HSD17B10 (0.76) | CDC7DBF4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | CDC7 196/4885DBF4 2117/4885PIM1 388/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | CDC7 196/4885DBF4 2117/4885PIM1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.